Generic drug freedom-to-operate isn’t about “avoiding patents.” It’s about outmaneuvering them.
In the generic industry, the phrase “picket fence” gets used like shorthand—but it’s really a warning label. If you’re a generic manufacturer, every paten…
Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System—Explained
In pharma, “protection” isn’t one thing. It’s two.
And if you’re investing, building a pipeline, negotiating partnerships, or even just trying to understand wh…
First-to-File, First-to-Profit: The Real Strategic Value of Paragraph IV + 180-Day Exclusivity
Most people treat Paragraph IV certifications like a legal checkbox—something you file, litigate, and move on from. But in branded pharma, Paragraph IV is le…
South America’s drug patent landscape isn’t “messy”—it’s strategic. And if you’re treating it like a single market, you’re likely missing the real story: the rules of exclusivity, enforcement, and pipeline protection vary dramatically country by countr…
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Biopharma’s “Patent Cliff” Isn’t Just a Legal Event—it’s a Commercial Deadline.
If you’re in biopharma commercial, market access, or business development, you already know the headline: patents expire, generics and biosimilars arrive, and pricing press…
Biopharma is entering a new talent cycle—and the “next place” isn’t a lab, a clinic, or even a specific therapeutic area.
It’s the patent landscape.
A recent analysis from DrugPatentWatch on biosimilar patent wars makes a point that should be impossibl…
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
The internet keeps asking: “Can this drug do that?” The science answer is: sometimes—but the real story is how we learn.
Every day, someone somewhere posts a question that starts with a familiar phrase: “Can this drug do X?” A new study drops. A viral …
Can This Drug…Do That? The internet keeps asking. The pharmacology keeps sighing. Read Post »
Stop DIY Drug Patent Searches—A New FTO Opinion Warning Should Change How You Manage Risk
If you’re in pharma, biotech, or medtech, you already know the uncomfortable truth: “We checked the patents” is not the same thing as “We’re protected.”
A recen…
Drug patent cliffs don’t just threaten revenue—they reshape procurement. Here’s how to win before exclusivity ends.
The industry has a familiar script: a blockbuster approaches loss of exclusivity, generics line up, and margins compress. But there’s a …
Most pharma teams don’t lose patent value because they miss deadlines—they lose it because they pick the wrong patent to extend.
That’s the uncomfortable truth behind “one-shot” patent strategy: when you’re trying to maximize drug patent term extension…
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »